Skandinaviska Enskilda Banken AB publ Boosts Stock Position in Illumina, Inc. $ILMN

Skandinaviska Enskilda Banken AB publ raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 32.6% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 74,195 shares of the life sciences company’s stock after buying an additional 18,253 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Illumina were worth $7,046,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Loomis Sayles & Co. L P boosted its stake in shares of Illumina by 1.9% during the second quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock valued at $403,158,000 after purchasing an additional 78,317 shares during the period. AQR Capital Management LLC lifted its holdings in Illumina by 55.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock valued at $313,290,000 after buying an additional 1,174,295 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Illumina by 0.7% during the 2nd quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock valued at $272,921,000 after buying an additional 21,342 shares in the last quarter. Bank of America Corp DE boosted its position in Illumina by 1.9% in the 2nd quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock valued at $184,222,000 after buying an additional 35,167 shares during the period. Finally, Edmond DE Rothschild Holding S.A. grew its stake in Illumina by 140.1% in the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company’s stock worth $136,312,000 after acquiring an additional 833,750 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the sale, the senior vice president owned 16,321 shares of the company’s stock, valued at $1,896,173.78. This trade represents a 12.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the transaction, the insider directly owned 17,887 shares in the company, valued at $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Wall Street Zen raised Illumina from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 14th. TD Cowen reissued a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Illumina in a report on Monday, December 29th. Evercore set a $150.00 price objective on shares of Illumina in a research note on Friday, February 6th. Finally, Robert W. Baird set a $137.00 target price on shares of Illumina in a research report on Friday, February 6th. Six analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $127.94.

Illumina Price Performance

ILMN opened at $120.00 on Friday. The firm has a market capitalization of $18.35 billion, a PE ratio of 22.02, a price-to-earnings-growth ratio of 2.30 and a beta of 1.45. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. The business’s 50-day moving average is $136.15 and its two-hundred day moving average is $116.94. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $155.53.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The company’s revenue was up 5.0% compared to the same quarter last year. During the same period last year, the business earned $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.